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While microRNAs (miRNAs) and the KRAS oncogene are known to be dysregulated in various cancers, little is known
about the role of miRNAs in the regulation of KRAS in cancer. Here we review a selection of studies published in
2014 that have contributed to our understanding of the molecular mechanisms of KRAS regulation by miRNAs and
the clinical relevance of sequence variants that may interfere with functional miRNA-mediated KRAS regulation.
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Since their discovery about two decades ago, the pro-
found role of microRNAs (miRNAs) in various aspects
of cancer is being uncovered including in cancer therapy
[1,2]. MiRNAs modulate a wide range of biological pro-
cesses, such as cellular proliferation, differentiation and
apoptosis, canonically by binding to the 3′ UTR of mRNAs
by partial complementarity and inhibiting mRNA stability
and translation. Since oncogenic KRAS is frequently found
in many cancers, including colon, pancreatic, and lung
cancer, and different cancer types and stages exhibit dis-
tinctive miRNA profiles, the regulation of KRAS by miRNAs
has drawn attention in the field. The KRAS oncogene,
which encodes a GTPase signaling protein, is a key driver
of complex, multistep tumorigenesis, as alteration and ac-
tivation of the gene and its pathway lead to acquisition of
cancerous properties [3].
Here we review the studies published in 2014 that ex-
plored miRNA-mediated regulation of KRAS in different
cancers. We briefly discuss the tumor-suppressive role
of miRNAs that target and regulate KRAS and the regu-
lation of those miRNAs (Table 1). In addition, the clinical
potential of sequence variants in the 3′ UTR of KRAS
(Table 2) as a cancer biomarker by altering the function
of miRNAs is discussed.
MiRNAs that target and regulate KRAS act as tumor suppressors
The seminal study by Johnson et al. identified the let-7
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unless otherwise stated.known to target and regulate KRAS [4]. Subsequently,
other tumor-suppressive miRNAs, including miR-96,
miR-30c and miR-181a, have shown to regulate KRAS in
various cancers [5-7]. More recently, Gastaldi et al. have
utilized a large scale profiling technology, small RNA se-
quencing, to profile miRNAs in cutaneous squamous cell
carcinomas (cSCCs) and identified the miR-193b/365a
cluster as one of the most prominently down-regulated
miRNAs in murine skin tumor progression [8]. Their role
as a tumor suppressor was confirmed in both mouse and
human epidermis, as these two miRNAs modulated cellu-
lar proliferation, migration and clonogenic potential.
Functional assays that showed an inverse relationship be-
tween the miRNAs and KRAS protein levels validated that
the two miRNAs functioned through targeting KRAS.
Additionally, the effects of the miRNAs were recapitulated
with KRAS knockdown in squamous carcinoma cells [8].
While several miRNA expression profiles report de-
regulation of numerous miRNAs in various cancers, only
a few miRNAs have been characterized. Liao et al. fur-
ther investigated the role of miR-30b, one of the known
down-regulated miRNAs in colorectal cancer (CRC) [9].
The clinical relevance of miR-30b was shown in a cohort
of 91 CRC cases, in which the level of miR-30b was
correlated with poor progression and survival. Ectopic
expression and inhibition of miR-30b affected cellular
proliferation in CRC cell lines and tumor growth in a
xenograft mouse model as miR-30b promotes G1
cell-cycle arrest and apoptosis. The effect of miR-30b
in tumor growth was mediated through targeting
many genes including KRAS [9].l Ltd. This is an Open Access article distributed under the terms of the Creative
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Table 1 MiRNAs that regulate KRAS cited in this Research
Highlight
miRNA Cancer type Reference
let-7 Lung cancer [4]
miR-96 Pancreatic cancer [5]
miR-30c Hereditary breast cancer [6]
miR-181a Oral squamous cell carcinoma [7]
miR-193b/365a Cutaneous squamous cell
carcinoma (cSCC)
[8]
miR-30b Colorectal cancer (CRC) [9]
miR-96 Pancreatic ductal adenocarcinoma (PDAC) [10]
miR-134 Glioblastoma (GBM) [11]
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As shown in the two above-mentioned studies, as well as
many others, many miRNAs have shown to target and regu-
late KRAS in cancer. However, the mechanisms by which
those miRNAs are regulated may lead to a better under-
standing of cancer development and an opening of new
therapeutic approaches. Two recent studies revealed how
two KRAS targeting miRNAs are regulated transcription-
ally and by other factors in the signaling pathway.
In a cohort of 224 human pancreatic neoplasms, Tanaka
et al. reported a widespread overexpression of EVI1 onco-
genic transcriptional factor in pancreatic ductal adeno-
carcinoma (PDAC) precursors and PDAC [10]. The group
also uncovered that EVI1 functioned in proliferation and
migration in pancreatic cancer cells and can modulate
KRAS protein levels and KRAS-ERK pathway by transcrip-
tionally regulating miR-96 and miR-181. Ectopic introduc-
tion of miR-96, but not miR-181, decreased KRAS protein
expression and resulted in cell cycle arrest in cells, suggest-
ing miR-96 as a tumor suppressor in EVI1-mediated KRAS
regulation [10].
Using miRNA microarrays, Zhang et al. found that the
MET receptor tyrosine kinase regulated miR-134 in glio-
blastoma (GBM) cells and glioblastoma stem cells (GSCs)
[11]. Additionally, while miR-134 was down-regulated,
multiple receptor tyrosine kinases (RTKs), MET, EGFR
and PDGFR, were activated in GBM cells, GSCs and hu-
man tumors. The tumor-suppressive property of miR-134Table 2 SNPs in the 3′ UTR of KRAS associated with
cancer
SNP ID Association with cancer Reference
rs61764370
(KRAS-variant)
Risk of non small-cell lung cancer, epithelial
ovarian cancer, triple-negative breast cancer,
colorectal cancer. Drug response in
metastatic colorectal cancer
[12-16,18,19]
rs712 Risk of oral squamous cell carcinoma,
gastric cancer, colorectal cancer,
papillary thyroid cancer
[25-28]was confirmed when overexpression of miR-134 inhibited
proliferation in GBM cells and tumor growth in GSC-
derived xenografts by targeting KRAS and STAT5B.
MiR-134 regulation by RTK was mediated by MAPK and
KLF4 transcription factor [11].
Sequence variants as potential effectors in miRNA-mediated
regulation of KRAS
In addition to dysregulation of miRNAs, sequence variants
in the 3′ UTR of target mRNAs can affect their gene regu-
lation. By sequencing the regions of the 3′ UTR of KRAS
in multiple non-small cell lung cancer (NSCLC) cases,
rs61764370 (also known as the KRAS-variant) was identi-
fied as the first single nucleotide polymorphism (SNP)
within a let-7 complementary site to be a biomarker for
NSCLC risk [12]. The KRAS-variant has shown to func-
tion as a biomarker for risk of certain cancer types [13-16]
and endometriosis [17], as well as a predictor for drug re-
sponse [18,19]. However, the universality of this marker
remains to be further investigated as some studies failed
to show an association between the KRAS-variant and
cancer risk [20,21] and drug response [22]. In addition,
two recent studies on the patients enrolled in clinical trials
found no association between stage 3 colon cancer and
the variant in a large cohort [23], and no significant asso-
ciation between endometrial cancer and the variant due to
a limited sample size [24].
Additional sequence variants in the 3′ UTR of KRAS
have been actively searched for and tested for their poten-
tial as biomarkers. While not as extensively validated as
the KRAS-variant, another SNP in the 3′ UTR of KRAS,
the rs712 variant, is being assayed as a biomarker for risk
of oral squamous cell carcinoma, gastric, colorectal and pap-
illary thyroid cancer [25-28]. Although no novel NSCLC-
associated variant was identified from a recent effort by
Kim et al. due to a small sample size [29], this study, as
well as a study by Sabarinathan et al. [30] suggested that
some SNPs can disrupt proper miRNA-mediated KRAS
regulation by destroying miRNA complementary sites and
changing the secondary structures of the RNA.
Conclusions and future directions
Understanding the molecular mechanism of miRNA-
mediated regulation of KRAS by characterizing tumor
suppressive miRNAs and oncoproteins that regulate
tumor suppressive miRNAs in the KRAS signaling path-
way would be beneficial for developing treatments in the
clinic. In addition, the discovery of a validated sequence
variant as a cancer biomarker for prognosis, diagnosis
and treatment response would provide a valuable clinical
tool. For example, many studies are examining the po-
tential of the KRAS-variant as a cancer biomarker. How-
ever, the universal clinical relevance of the KRAS-variant
remains unclear. Since cancer is a very heterogeneous
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tion, age and external factors can affect the outcome,
rigorous case-control studies are warranted to confirm
the clinical application of variants as biomarkers for spe-
cific cancers.
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